Zucara Therapeutics
2405 Wesbrook Mall
Fourth Floor
Vancouver
British Columbia
V6T 1Z3
Canada
Website: http://www.zucara.ca/
About Zucara Therapeutics
Zucara, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is a company with a novel drug therapy to help prevent hypoglycemia in people with diabetes. It is advancing novel technology that is showing promise as a long-term therapeutic approach to prevent hypoglycemia in people with diabetes who are insulin-dependent.YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Michael Midmer, MSc, MBA
CBO: Jonathon Jafari, MSc, MBA
CSO: Richard Liggins, PhD
Chair, Scientific Advisory Board: Michael Riddell, PhD
Director, Technology & Venture Development: Dominic Jaikaran, PhD, MBA
TECHNOLOGY
Please click here for Zucara's technology.
18 articles about Zucara Therapeutics
-
Zucara Therapeutics Doses First Patient in Phase 2a 'ZONE' Trial
9/25/2023
Zucara Therapeutics Inc., today announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes ("T1D") mellitus ("ZONE").
-
Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study
6/15/2023
Zucara Therapeutics Inc. announced additional funding from JDRF, the leading global Type 1 diabetes research and advocacy organization.
-
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01
4/19/2023
Zucara Therapeutics Inc., today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for ZT-01 for the prevention of night-time (nocturnal) hypoglycemia in patients with Type 1 Diabetes ("T1D").
-
Zucara Therapeutics' Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01
9/19/2022
Zucara Therapeutics Inc., today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.
-
Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01
6/22/2022
Zucara Therapeutics Inc. today announced that its Phase 1b proof-of-concept trial demonstrated ZT-01's ability to restore glucagon release in people with Type 1 diabetes ("T1D").
-
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01
5/2/2022
Zucara Therapeutics Inc. today announced that it has received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes ("T2D").
-
Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01's Ability to Restore Glucagon Release in Type 1 Diabetes
2/8/2022
Zucara Therapeutics Inc. today announced that the peer-reviewed journal, Diabetes, Obesity and Metabolism, has published a paper reporting positive preclinical data showing the effect and pharmacokinetics of ZT-01.
-
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
-
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
7/28/2021
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.
-
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
5/26/2021
Zucara Therapeutics Inc. a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01.
-
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes– ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding –
11/2/2020
Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). The development of ZT-01 for T2D will be supported, in part, by advisory services and up to $415,000 in non-diluti
-
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01– Phase 1 Trial to Evaluate ZT-01 for the Prevention of Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes –
9/29/2020
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01.
-
Zucara Therapeutics Announces US$21 Million Series A Financing
3/31/2020
Zucara Therapeutics Inc. announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund.
-
Zucara Therapeutics Secures US$3.9M from the Helmsley Charitable Trust to Advance Diabetes Drug Candidate to Clinical Trials
4/9/2018
Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust.
-
Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate
2/9/2018
Zucara recently defined its lead drug candidate, ZT-01, and this support will enable Zucara to conduct critical validation work and further advance ZT-01 through preclinical testing.
-
JDRF Funds Zucara Therapeutics' Approach To Preventing Hypoglycemia In People With Type 1 Diabetes
9/21/2017
-
Zucara Therapeutics And The Centre For Drug Research And Development Complete Licensing Deal To Select Lead Therapeutic Drug Candidate
10/14/2016
-
Zucara Therapeutics Appoints Michael Midmer As CEO
9/12/2016